ZLZhiwei Liao

Zhiwei Liao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhiwei Liao has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Lei Sun

    Department of Radiation Oncology, Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, China

    2 shared publications
  • Linjing Wang

    Radiotherapy center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Yawei Yuan

    Department of Radiation Oncology, Affiliated Cancer Hospital & institute of Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Bo-Jun Tu

    Department of Radiation Oncology, Affiliated Tumor Hospital of Guangzhou Medical College, No.78 Hengzhigang Road Yuexiu District, Guangzhou 510095, China

    1 shared publication
  • Chao Wang

    Department of Pathology, Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    1 shared publication
  • Hui Yu

    Radiotherapy center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Network-based single-cell analysis identifies a proliferative GZMB+ plasma cell subset linked to Hedgehog signaling and prognostic risk in lung squamous cell carcinoma

    by Wen Ma, Junjie Kuang, Xiaoye Hu, Shaohui Huang, Jie Zhou, Zhiwei Liao, Yan Yuan

    Lung squamous cell carcinoma (LUSC) is a heterogeneous cancer characterized by complex cellular interactions. Plasma cells, a critical immune population, e

  • Open Access

    A deep learning model for the diagnosis of gastric neuroendocrine carcinoma

    by Tianchen Zhu, Zihan Zhao, Chao Wang, Xinke Zhang, Lin Zheng, Wenxu Chen, Zhengyi Zhou, Zhiwei Liao, Yan Huang, Muyan Cai, et al.

    Background Gastric neuroendocrine carcinoma (G-NEC) presents with clinical and pathological features that closely resemble those of gastric adenocarcinoma (GC), often complicating differential diagnosis. However, G-NEC is markedly more aggressive and associated with a significantly poorer prognosis, necessitating accurate and timely identification to guide appropriate therapeutic interventions. Methods In response to this clinical need, we developed G-NECNet, a deep convolutional neural network tailored to detect G-NEC from histopathological whole-slide images. Results The model demonstrates excellent diagnostic performance, yielding an average area under the receiver operating curve (AUROC) of 0.993 in the internal validation cohort, 0.985 on an external single-institutional dataset, and 1.000 on an external multi-institutional consultation dataset. These consistently high AUROC values highlight the robustness, accuracy, and generalizability of G-NECNet across diverse clinical settings. Conclusions The integration of G-NECNet into routine diagnostic workflows may not only improve the precision of G-NEC classification but also reduce misdiagnosis-related healthcare costs, offering a practical and scalable solution for clinical application.


  • 4DCT ventilation function image-based functional lung protection for esophageal cancer radiotherapy

    by Pixiao Zhou, Ruihao Wang, Hui Yu, Zhiwei Liao, Ying Zhang, Zouqin Huang, Shuxu Zhang

    Background 4DCT (four-dimensional computed tomography) can effectively obtain functional lung ventilation images for patients and integrate them into radiotherapy treatment planning. Studies have not been performed on esophageal cancer, and there is no clear consensus on the optimal functional lung threshold for functional lung. Methods Functional lung images were generated for 11 patients with esophageal cancer. The correlation between the dose–volume parameters of functional lung (FL) as defined by different thresholds and the change of PFT/PDFT (pulmonary [diffusion] function test) metrics before and after radiotherapy were evaluated. FL-sparing planning was generated for each patient to preserve the functional lung and compared to conventional anatomical CT (non-sparing) planning. Results There was a significant positive correlation between the FL0.8 (defined Jacobian value ≤ 0.8), FL0.84, and FL0.9 dose–volume parameters and ΔFEV1/FVC (reduction before and after radiotherapy), and the FL0.8‑V30 correlation was the strongest (r = 0.819, P < 0.01). The FL-sparing planning had a target area conformity index and homogeneity index comparable to the non-sparing planning (P > 0.05). For FL, the FL-sparing planning achieved lower FL-MLD (6.30 ± 2.14 Gy vs. 7.83 ± 2.70 Gy), V10 (17.13 ± 7.70% vs. 27.40 ± 9.48%), and V20 (6.96 ± 3.85% vs. 11.63 ± 7.19%) compared to the non-sparing planning (P < 0.05), while heart and spinal cord doses were not significantly different between the two planning groups. Conclusion The 4DCT-based FL irradiation dose for esophageal cancer was significantly associated with a decrease in FEV1/FVC. The optimal FL defined as a Jacobian value ≤ 0.8 or about 21% of the whole lung volume may be a good choice. FL-sparing planning significantly reduced the FL dose without compromising target area coverage.


  • Open Access

    Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation

    by Jian-Man Zhu, Lei Sun, Linjing Wang, Tong-Chong Zhou, Yawei Yuan, Xin Zhen, Zhi-Wei Liao

    Objective: This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model is essential for accurate treatment outcome prediction. Our study were established 176 discrimination models constructed with 22 feature selection methods and 8 classifiers. The predictive performance of each model were evaluated using the AUC, ACC, sensitivity and specificity, where the optimal model was identified. Results: There were totally 107 radiomics features and 7 clinical features obtained from each patient. After feature selection, the top-ten most relevant features were fed to train 176 models. Significant performance variations were observed in the established models, with the best performance achieved by the logistic regression model using gini-index feature selection (AUC = 0.797, ACC = 0.722, sensitivity = 0.758, specificity = 0.693). The median R-score was 0.518 (IQR, 0.023–0.987), and the patients were divided into high-risk and low-risk groups based on this cut-off value. The KM survival curves of the two groups demonstrated evident stratification results (p = 0.000).


  • Open Access

    Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation

    by Jianman Zhu, Lei Sun, Linjing Wang, Tongchong Zhou, Yawei Yuan, Xin Zhen, Zhiwei Liao

    Objective:This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model is essential for accurate treatment outcome prediction. Our study were established 176 discrimination models constructed with 22 feature selection methods and 8 classifiers. The predictive performance of each model was evaluated using the AUC, ACC,sensitivity and specificity,where the optimal model was identified. Results:There were totally 107 radiomics features and 7 clinical features obtained from each patient. After feature selection, the top-ten most relevant features were fed to train 176 models.Significant performance variations were observed in the established models, with the best performance achieved by the logistic regression model using gini-index feature selection (AUC=0.797, ACC=0.722, sensitivity=0.758, specificity=0.693).The median R-score was 0.518 (IQR,0.023-0.987), and the patients were divided into high-risk and low-risk groups based on this cut-off value. The KM survival curves of the two groups demonstrated evident stratification results (p=0.000).

  • Open Access

    High expression of p300 is linked to aggressive features and poor prognosis of Nasopharyngeal Carcinoma

    by Zhi-Wei Liao, Tong-Chong Zhou, Xiao-Jun Tan, Xian-Lu Song, Yuan Liu, Xing-Yuan Shi, Wen-Jin Huang, Li-Li Du, Bo-Jun Tu, Xiao-Dan Lin

    Background: Increased expression of transcriptional coactivator p300 has been observed in a variety of human cancers. However, the expression status of p300 protein/mRNA in nasopharyngeal carcinoma (NPC) tissues and its clinicopathologic/prognostic implication are poorly understood.Methods: In our study, mRNA and protein expression levels of p300 was explored by reverse transcription-polymerase chain reaction (RT-PCR), Western blotting (WB) and immunohistochemistry (IHC) in nasopharyngeal mucosal and NPC tissues. The data were analyzed by receiver operating characteristic (ROC) curve analysis, spearman’s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model.Results: Up-regulated expression ofp300mRNA/p300 protein was detected in NPC tissues by RT-PCR and WB, when compared to nasopharyngeal mucosal tissues. Based on ROC curve analysis, the cutoff score for p300 high expression was defined when more than 35% of the tumor cells were positively stained. High expression of p300 was observed in 127/209 (60.7%) of NPCs. In NPCs, high expression of p300 was positively associated with later T classification, later N classification, distant metastasis and later clinical stage (P < 0.05). In univariate survival analysis, overexpression of p300 was found to be an indicator of progression-free (P = 0.002) and overall survival (P = 0.001) in NPCs. More importantly, p300 expression was evaluated as an independent prognostic factor for NPC in multivariate analysis (P = 0.036).Conclusions: Our findings support that high expression of p300 protein might be important in conferring a more aggressive behavior, and is an independent molecular marker for shortened survival time of patients with NPC.